dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Mylonakis, N. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Andreopoulou, E. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Mylonakis, N. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Samantas, E. | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Andreopoulou, E. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.date.accessioned | 2018-06-22T09:53:49Z | |
dc.date.available | 2018-06-22T09:53:49Z | |
dc.date.issued | 1997 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42039 | |
dc.description.abstract | Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using both agents in patients with inoperable stages III and IV disease to investigate the efficacy and toxicity of the combination. Patients and methods: Since July 1995, 60 patients fulfilling all eligibility criteria entered this study. All patients received paclitaxel 175 mg/m2 as a three- hour infusion, and carboplatin dosed to an area under the concentration-time curve of seven, every three weeks. No granulocyte colony-stimulating factor was given. Of the 56 male and four female patients, the median age was 57 years (range 29 to 75 years) and the median Eastern Co-Operative Oncology Group performance status was one. Most of the patients had stage IV (34) adenocarcinoma (31) with low differentiation (28). The median number of chemotherapy cycles was three, with a range of one to eight. Results: Of 55 evaluable patients, 15 (27.3%) achieved partial responses, 15 (27.3%) had astable disease, and 25 (45.4%) had progressive disease. The median survival was 8.95 months and 21.6% of the patients survived more than one year. Grade 2/3 nonhematologic toxicity included alopecia (59%), neurotoxicity (3%), and myalgia/arthralgia (10%). Grade 2/3 neutropenia occurred in 14% of patients, whereas grade 3/4 thrombocytopenia was seen in only 4%. One patient died of complications of a severe allergic reaction. Conclusion: Combination treatment using paclitaxel and carboplatin is active and well tolerated in patients with inoperable non-small-cell lung cancer. The dose-response relationship to paclitaxel and results of comparison with other platinum- based regimens remain to be determined. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Drug efficacy | en |
dc.subject | Leukopenia | en |
dc.subject | Myalgia | en |
dc.subject | Neurotoxicity | en |
dc.subject | Ondansetron | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Drug hypersensitivity | en |
dc.subject | Treatment outcome | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Carboplatin | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | Paclitaxel | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Nsclc | en |
dc.title | Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1008268911935 | |
dc.description.volume | 8 | |
dc.description.issue | 7 | |
dc.description.startingpage | 697 | |
dc.description.endingpage | 699 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |